[Form 3] ABBVIE INC. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

AbbVie Inc. (ABBV) filed a Form 3 disclosing the initial beneficial ownership of newly appointed EVP & Chief HR Officer Demetris D. Crum. As of the reportable event date 07/01/2025, Mr. Crum directly holds 7,048 shares of AbbVie common stock, a figure that includes 1,113 restricted stock units scheduled to vest in full on 02/16/2026.

The filing also lists two employee stock option grants made under the company’s 2013 Incentive Stock Program:

• 5,043 options at an exercise price of $175.28, expiring 02/14/2034; 1,681 shares became exercisable on 02/15/2025 with additional tranches in 2026 and 2027.
• 4,687 options at an exercise price of $192.86, expiring 02/12/2035; tranches vest annually from 2026-2028.

The filing is administrative, establishing Mr. Crum’s initial ownership under Section 16 reporting rules. No purchase or sale transactions are reported, and no new equity issuance by AbbVie is involved.

Insights

Financial Analyst

TL;DR: Routine Form 3 shows new EVP holds modest equity; no transactional impact.

This filing merely records Demetris Crum’s starting equity position as a section 16 insider. The 7,048 shares and 9,730 options represent a negligible fraction of AbbVie’s outstanding shares, so there is no valuation impact. While insider ownership can signal alignment with shareholders, the amounts disclosed are typical for senior executives and were granted previously under the incentive plan. No buying or selling activity is indicated, keeping the disclosure neutral for investors.

Corporate Governance Expert

TL;DR: Disclosure satisfies governance and compliance; informational only.

Section 16 rules require newly appointed officers to file Form 3 within 10 days. AbbVie meets this obligation, listing Crum’s equity awards and including a Power of Attorney. The staggered option vesting schedules match AbbVie’s standard retention practices. There are no red flags regarding concentration or unusual grant structures. Overall, the filing improves transparency but does not alter governance risk profiles.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

AbbVie Inc.

(Last) (First) (Middle)

1 NORTH WAUKEEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2025

3. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief HR Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock, $0.01 par value	7,048(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to buy)(2)	(2)	02/14/2034	Common Stock	5,043	$175.28	D
Option (Right to buy)(3)	(3)	02/12/2035	Common Stock	4,687	$192.86	D

Explanation of Responses:

1. Includes 1,113 restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. These restricted stock units vest in full on February 16, 2026, and include the right to have stock withheld for tax purposes.

2. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 1,681 shares on 2/15/2025, and will become exercisable as to 1,681 shares on 2/15/2026 and as to 1,681 shares on 2/16/2027.

3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 1,563 shares on 2/13/2026, as to 1,562 shares on 2/13/2027 and as to 1,562 shares on 2/13/2028.

Remarks:

This initial holding statement has been made for Demetris D. Crum using the Issuer's CIK codes in order to satisfy Form 3 filing requirements for newly appointed company officers. An amendment will be filed for Mr. Crum upon receipt of his CIK filer codes from the SEC. Exhibit 24 - Power of Attorney.

	/s/ T.O. Odutayo, Attorney-in-Fact for Demetris D. Crum	07/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many AbbVie (ABBV) shares does Demetris D. Crum currently own?

Mr. Crum directly owns 7,048 shares of AbbVie common stock, including 1,113 restricted stock units.

What stock options were disclosed in AbbVie’s July 2025 Form 3 filing?

Two option grants were reported: 5,043 options at $175.28 expiring 02/14/2034 and 4,687 options at $192.86 expiring 02/12/2035.

When will the restricted stock units reported in the Form 3 vest?

The 1,113 RSUs will vest in full on 02/16/2026.

Does the Form 3 indicate any recent purchase or sale of ABBV shares?

No. The filing is an initial ownership report; it records holdings but shows no transactions.

Why did AbbVie file this Form 3 on 07/11/2025?

Section 16 requires an initial statement of beneficial ownership within 10 days of becoming an officer. Mr. Crum’s appointment triggered the filing.